Norgine has announced that Swissmedic has approved the registration of IFINWIL (eflornithine) as a monotherapy for treating ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

The medicine, called Coartem Baby (also known as Riamet Baby), was approved by Switzerland’s health agency, Swissmedic.

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Switzerland’s health regulator Swissmedic granted marketing authorisation on Tuesday for Novartis Riamet Baby, also known as ...

IFINWIL®: now approved in Switzerland1Nine out of 10 cases of neuroblastoma occur in children under the age of five2The average survival rate of children with HRNB is only 50%2UXBRIDGE, England ...

Swissmedic approves Norgine’s Ifinwil for children diagnosed with high-risk neuroblastoma: Uxbridge, UK Thursday, July 10, 2025, 17:00 Hrs [IST] Norgine, a leading European spec ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants.

Norgine, a leading European specialty pharmaceutical company, announced that Swissmedic has approved the registration of Ifinwil (eflornithine) as monotherapy for the treatment of paediatric patients ...

By collaborating with international regulatory partners through Project Orbis, we are advancing our strategy to broaden ...